Genocea Biosciences, Inc. engages in the development and commercialization of cancer immunotherapies. The company is headquartered in Cambridge, Massachusetts and currently employs 74 full-time employees. The company went IPO on 2014-02-05. The firm is engaged in discovering and developing cancer immunotherapies using its proprietary ATLAS platform. The ATLAS platform can profile each patient's CD4+ and CD8+ T cell immune responses to every potential target or antigen identified by next-generation sequencing of that patient's tumor. ATLAS zeroes in on both antigens that activate anti-tumor T cell responses and inhibitory antigens, or Inhibigens, that drive pro-tumor immune responses. Its GEN-009 is an investigational neoantigen vaccine delivering adjuvanted synthetic long peptides from ATLAS-identified neoantigens. The firm has a license agreement with Harvard College (Harvard), granting the Company a sublicensable license to one patent family, to develop, make, use, market licensed products, and perform licensed services related to the ATLAS discovery platform.
Follow-Up Questions
What is Genocea Biosciences Inc (GNCAQ)'s P/E Ratio?
The P/E ratio of Genocea Biosciences Inc is 0
Who is the CEO of Genocea Biosciences Inc?
Mr. William Clark is the President of Genocea Biosciences Inc, joining the firm since 2010.
What is the price performance of GNCAQ stock?
The current price of GNCAQ is $0, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Genocea Biosciences Inc?
Genocea Biosciences Inc belongs to Biotechnology industry and the sector is Health Care
What is Genocea Biosciences Inc market cap?
Genocea Biosciences Inc's current market cap is $58.779999999999994
